Where Will Rocket Lab Stock Be by This Time Next Year?

Rocket Lab shares have fallen 57% from their late-May peak amid expected Neutron delays into 2027 and its planned $8 billion acquisition of Iridium, a substantial deal relative to Rocket Lab's $38 billion market capitalization. Despite continued unprofitability, the company has a $2.36 billion backlog versus $434 million in first-half 2026 reportable business, supported by customers including NASA and the U.S. Department of Defense. Analysts rate RKLB a strong buy with a $113.76 12-month target, implying more than 70% upside, though execution risks around Neutron and the Iridium transaction remain material.

Analysis

The central investable question is not Neutron timing alone, but whether RKLB can finance an $8B acquisition without impairing its ability to complete Neutron and scale production. At that transaction size, a stock-funded deal would create substantial dilution and a debt-funded structure would raise interest expense and refinancing risk for a company still consuming cash; either path can cap the equity multiple until definitive financing terms are disclosed. The market is likely assigning little value to backlog beyond its execution-adjusted margin, appropriately so until management demonstrates that satellite systems conversion can offset launch-development cash burn.

IRDM could be strategically valuable because its contracted connectivity revenue and spectrum/constellation assets may lower RKLB's revenue cyclicality and create vertical integration opportunities with spacecraft manufacturing. But integration has a non-obvious downside: combining a service operator with a launch-and-hardware company adds customer-concentration, constellation-replacement, and regulatory complexity precisely when RKLB needs management focus on Neutron. VSAT is a potential second-order beneficiary if uncertainty around IRDM customer/service continuity drives government and maritime customers to diversify procurement.

Over the next days, RKLB remains vulnerable to financing headlines, revised Neutron milestones, and any disclosure that consideration materially exceeds the implied standalone value of IRDM. Over 1-3 months, a credible capital plan and preserved liquidity runway could rerate shares; over 6-18 months, the key falsifier is not launch publicity but whether segment gross margin, operating cash flow, and backlog conversion improve while development spending remains controlled. The consensus upside target is not independently actionable without updated diluted-share, net-debt, and pro forma cash-flow estimates.

Key Decisions for Investors

• Do not add directional RKLB exposure before the merger agreement, consideration mix, pro forma liquidity, and termination provisions are available. Establish an alert for a financing package that keeps post-deal net leverage modest and avoids a large discounted equity issuance; absent that, treat rallies as opportunities to reduce rather than initiate.
• For high-risk accounts only, consider a small 6-12 month RKLB call spread rather than common equity after financing disclosure—for example, buy an at-the-money call and sell a 30-40% out-of-the-money call—to participate in a de-risking rerating while defining loss. Exit if Neutron timing slips again or quarterly cash burn accelerates despite satellite-systems revenue growth.
• Monitor IRDM's trading spread to the announced consideration once terms are filed. A long IRDM / short RKLB merger-arbitrage position is only actionable if the consideration is predominantly fixed shares, the implied spread compensates for closing and financing risk, and borrow is available; no recommendation can be made before those inputs are known.
• Maintain VSAT as a watch-list hedge rather than a core long: evidence of government, maritime, or aviation customer diversification away from an integrating IRDM could improve VSAT order momentum over the next 2-4 quarters. Falsify on stable IRDM retention metrics and no measurable VSAT bookings improvement.